B-Type Natriuretic Peptide: A Cardiac Stress Signal
B-type natriuretic peptide (BNP), also known as brain natriuretic peptide (originally identified in porcine brain tissue but predominantly produced by the heart), is a 32-amino acid polypeptide hormone released primarily from ventricular cardiomyocytes in response to myocardial wall stress - specifically, when the heart muscle is stretched by increased blood volume or pressure. BNP has become one of the most valuable biomarkers in cardiovascular medicine, particularly for the diagnosis, risk stratification, and monitoring of heart failure.
BNP Biology and Function
BNP is synthesized as a preprohormone (preproBNP, 134 amino acids), which is cleaved to proBNP (108 amino acids) and then further cleaved by the enzyme corin to produce the active BNP (32 amino acids) and the inactive N-terminal fragment NT-proBNP (76 amino acids). Both BNP and NT-proBNP are released into the circulation, and both are clinically useful biomarkers, though with different half-lives and reference ranges[1].
Physiological Actions of BNP
BNP acts as a counter-regulatory hormone to the renin-angiotensin-aldosterone system (RAAS), helping protect the heart from volume overload:
- Vasodilation: Relaxes vascular smooth muscle, reducing afterload (the resistance the heart pumps against)
- Natriuresis and diuresis: Promotes sodium and water excretion by the kidneys, reducing blood volume and preload
- RAAS suppression: Inhibits renin secretion and aldosterone production, counteracting sodium and water retention
- Anti-fibrotic: Reduces cardiac fibrosis and hypertrophy signaling
- Sympatholytic: Reduces sympathetic nervous system activation
What High BNP Levels Mean
Elevated BNP indicates that the heart is under increased stress - typically due to volume overload, pressure overload, or myocardial dysfunction. The higher the BNP level, the greater the degree of cardiac stress:
BNP Reference Ranges and Interpretation
- <100 pg/mL: Heart failure unlikely (negative predictive value >95%)
- 100-400 pg/mL: Gray zone - may indicate mild heart failure, pulmonary disease, renal impairment, or other conditions
- >400 pg/mL: Heart failure likely - sensitivity of approximately 95% for symptomatic HF
- >900-1000 pg/mL: Severe heart failure with high short-term mortality risk
NT-proBNP ranges differ: <300 pg/mL excludes HF; >450 (age <50), >900 (50-75), or >1800 (age >75) suggest HF
Clinical Applications
Heart Failure Diagnosis
BNP's primary clinical role is in the emergency department evaluation of acute dyspnea (shortness of breath). When a patient presents with dyspnea, BNP testing helps distinguish cardiac causes (heart failure) from pulmonary causes (COPD exacerbation, pneumonia, pulmonary embolism):
- BNP <100 pg/mL effectively rules out heart failure as the cause of dyspnea
- BNP >400 pg/mL, combined with clinical findings, confirms heart failure with high confidence
- The Breathing Not Properly study demonstrated that BNP at a cutoff of 100 pg/mL had 90% sensitivity and 76% specificity for heart failure
Heart Failure Monitoring
Serial BNP measurements track treatment response and guide therapy adjustments:
- A decrease of >30% from baseline indicates meaningful clinical improvement
- Persistently elevated BNP despite treatment suggests inadequate response and need for therapy escalation
- Pre-discharge BNP levels predict 30-day readmission risk
Risk Stratification
BNP provides prognostic information across multiple cardiac conditions:
- Acute coronary syndrome: Elevated BNP predicts larger infarct size and higher mortality
- Valvular heart disease: Rising BNP indicates worsening hemodynamic significance
- Pulmonary hypertension: BNP correlates with right ventricular strain
- Atrial fibrillation: Elevated BNP predicts stroke risk and adverse outcomes[2]
Factors Affecting BNP Levels
Accurate interpretation requires awareness of non-cardiac factors that influence BNP:
- Age: BNP increases with age; age-adjusted cutoffs improve diagnostic accuracy
- Obesity: BNP levels are paradoxically lower in obese patients (adipose tissue expresses natriuretic peptide clearance receptors), potentially causing false negatives
- Renal impairment: Reduced renal clearance elevates BNP and especially NT-proBNP
- Sex: Women have slightly higher baseline BNP levels than men
- Pulmonary disease: Cor pulmonale and pulmonary embolism can elevate BNP through right ventricular strain
- Sepsis: Can elevate BNP through myocardial depression
BNP vs. NT-proBNP
Both biomarkers provide similar clinical information, but with practical differences:
| Feature | BNP | NT-proBNP |
|---|---|---|
| Half-life | ~20 minutes | ~120 minutes |
| Clearance | Neutral endopeptidase + renal | Primarily renal |
| Stability | Less stable in vitro | More stable (easier processing) |
| Renal effect | Moderate influence | Greater influence by GFR |
| Sacubitril/valsartan | Increases BNP (inhibits clearance) | NT-proBNP unaffected (preferred for monitoring) |
